Diabetic Kidney Disease Clinical Trial
Official title:
Diagnostic Value of Serum Cathepsin S and Chromogranin A in Diabetic Kidney Disease
1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease. 2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.
Diabetic nephropathy (DN) is a common and serious complication of diabetes and has been shown to be a major cause of end-stage renal disease (ESRD), requiring costly renal replacement therapy in the form of dialysis or transplantation . It is appreciated that up to 40% of patients with type 1 and type 2 diabetes mellitus (DM) present DN . Early detection and appropriate treatment are essential to prevent disability and death. Cathepsin S (Cat-S) was a secreted cysteine proteolytic enzyme that is mainly expressed in macrophages. Macrophages undergoing chemotaxis adhere to the basement membrane of blood vessels and secrete Cat-S, and the secreted Cat-S was involved in hydrolysis of elastin, laminin, collagen and other extracellular matrix components, causing vascular damage . So, Cathepsin S(Cat-S), a novel non-invasive diagnostic marker mediates vascular endothelial dysfunction. In recent years, studies have shown that up regulation of Cat-S was associated with the development of IgA nephropathy, lupus nephritis, insulin resistance, diabetes and other renal diseases. Chromogranin A (CgA) is the main member of the chromogranin family and is an acidic glycoprotein consisting of 439 amino acids with an approximate molecular mass of 48 kDa. CgA is used as a diagnostic marker of neuroendocrine tumors(6). The kidney is the main site for the removal of CgA, and it is retained in serum with declining renal function. In patients with renal failure, serum CgA increases much more than creatinine and the other studied low-MW proteins. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06006689 -
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
|
Phase 2 | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT05086549 -
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
|
||
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
| Not yet recruiting |
NCT06120569 -
Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients
|
N/A | |
| Completed |
NCT02545049 -
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
|
Phase 3 | |
| Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
| Active, not recruiting |
NCT06176599 -
Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis
|
N/A | |
| Recruiting |
NCT03716401 -
Prognostic Imaging Biomarkers for Diabetic Kidney Disease
|
||
| Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
| Completed |
NCT01377688 -
Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes
|
N/A | |
| Active, not recruiting |
NCT05514548 -
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
|
Phase 2 | |
| Recruiting |
NCT05507892 -
Renal Mechanism of SGLT2 Inhibition
|
Phase 2 | |
| Not yet recruiting |
NCT06049550 -
The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
|
||
| Not yet recruiting |
NCT05514184 -
Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease
|
N/A | |
| Active, not recruiting |
NCT04589351 -
Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
|
Phase 3 | |
| Active, not recruiting |
NCT04531163 -
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
| Suspended |
NCT01878045 -
Mechanisms of Diabetic Kidney Disease in American Indians
|